<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001873'>Thrombocytopenia</z:hpo> is a frequent symptom and clinical challenge in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Eltrombopag is a small molecule thrombopoietin receptor <z:chebi fb="4" ids="48705">agonist</z:chebi> that might be a new option to treat <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in these diseases, provided that it does not stimulate malignant hematopoiesis </plain></SENT>
<SENT sid="2" pm="."><plain>In this work, we studied the effects of Eltrombopag on proliferation, <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, differentiation, colony formation, and malignant self-renewal of bone marrow mononuclear cells of patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Malignant bone marrow mononuclear cells did not show increased proliferation, or increased clonogenic capacity at concentrations of Eltrombopag ranging from 0.1 to 30 microg/mL </plain></SENT>
<SENT sid="4" pm="."><plain>On the contrary, we observed a moderate, statistically nonsignificant (P = .18), decrease of numbers of malignant cells (mean, 56%; SD, 28%) </plain></SENT>
<SENT sid="5" pm="."><plain>Eltrombopag neither led to increased 5-<z:chebi fb="1" ids="22927,47265">bromo</z:chebi>-2-deoxyuridine incorporation, <z:mp ids='MP_0006043'>decreased apoptosis</z:mp>, an increase of malignant self-renewal, nor enhanced in vivo engraftment in xenotransplantations </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, we found that Eltrombopag was capable of increasing megakaryocytic differentiation and formation of <z:mpath ids='MPATH_458'>normal</z:mpath> megakaryocytic colonies in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>These results provide a preclinical rationale for further testing of Eltrombopag for treatment of <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>